## Laura Martin de la Fuente

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4128429/publications.pdf

Version: 2024-02-01

1684188 1720034 7 141 5 7 citations g-index h-index papers 7 7 7 279 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. Molecular and Cellular Proteomics, 2019, 18, 1836-1850.	3.8	42
2	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 83-91.	2.8	41
3	Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response. International Journal of Gynecological Pathology, 2018, 37, 101-109.	1.4	31
4	Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method. Scientific Reports, 2019, 9, 15506.	3.3	10
5	SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery. Molecular and Cellular Oncology, 2020, 7, 1805094.	0.7	7
6	MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. Genes, 2021, 12, 742.	2.4	6
7	High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. Gynecologic Oncology, 2020, 159, 860-868.	1.4	4